ABSTRACT
The Islamic precept of R implies important physiological modifications due to the hydric and dietetic restrictions along a whole month plus a day, all of which have a crucial repercussion over the physical and intellectual performance of Muslims, particularly in occidental societies, in which there is no hour readjustments for daily activities. Among the imposed modifications by Ramadan in daily habits, intermittent fasting along day and night causes adaptation mechanisms to optimize the energy consumption. The objective of this study was to analyze the metabolic-endocrine changes that happen during daily working hours, along the month of fasting in young subjects who have to continue their usual activities and sport training. Ten young muslim subjects, male, healthy, set to sport training, ages in between 18 and 25 who completed Ramadan. Plasma biochemical and hormonal parameters were analyzed in plasma, a week before Ramadan, in the first and fourth of the fasting month and a week after conclusion. During Ramadan, have been observed a drop of biochemical parameters along daytime, especially those related to glycemia, being these changes stronger in the first week. The concentration of cortisol found to be significantly high during the whole month as a consequence of adaptation to the change of circadian secretion rhythms. Ramadan obliges subject's organisms to readjust their endocrine and metabolic system in order to preserve the energetic efficiency during daytime. This auto control becomes more efficient as long as the month advances due to physiological adaptations.
Subject(s)
Adaptation, Physiological/physiology , Athletic Performance/physiology , Energy Intake/physiology , Fasting/metabolism , Islam , Adolescent , Adult , Athletes , Fasting/physiology , Humans , Male , Young AdultABSTRACT
El precepto islámico del Ramadán (R), implica importantes modificaciones fisiológicas debido a las restricciones hídricas y dietéticas a lo largo del día y durante un mes, lo que tiene una especial repercusión física e intelectual de los musulmanes, particularmente en sociedades occidentales, en las que no se producen reajustes horarios para las actividades cotidianas. Entre las modificaciones impuestas por el R, el ayuno intermitente día/noche, desencadena mecanismos de adaptación para rentabilizar el consumo energético. El objetivo del presente estudio ha sido valorar algunos cambios endocrinometabólicos que acontecen a lo largo de la jornada, durante el mes de ayuno, en jóvenes que tienen que continuar con su actividad y entrenamiento deportivo habitual. Diez jóvenes musulmanes, varones, sanos, sometidos a entrenamiento deportivo, con edades entre 18 y 25 años que realizaron el R. Se analizaron parámetros bioquímicos y hormonales en plasma, una semana previa al R, primera y cuarta del periodo de ayuno (mañana y tarde) y semana posterior. Durante el R, se observa un descenso de los parámetros bioquímicos a lo largo del día, especialmente de la glucemia, siendo estos cambios más evidentes en la primera semana. La concentración de cortisol se encuentran significativamente elevada durante todo el mes, como consecuencia del cambio de ritmo circadiano de secreción. El R obliga al organismo a un ajuste endocrino-metabólico con el fin de preservar la eficiencia energética durante la jornada. Este control se vuelve más eficaz conforme avanza el mes de ayuno y la consecuente adaptación fisiológica.
The Islamic precept of R implies important physiological modifications due to the hydric and dietetic restrictions along a whole month plus a day, all of which have a crucial repercussion over the physical and intellectual performance of Muslims, particularly in occidental societies, in which there is no hour readjustments for daily activities. Among the imposed modifications by Ramadan in daily habits, intermittent fasting along day and night causes adaptation mechanisms to optimize the energy consumption. The objective of this study was to analyze the metabolic-endocrine changes that happen during daily working hours, along the month of fasting in young subjects who have to continue their usual activities and sport training. Ten young muslim subjects, male, healthy, set to sport training, ages in between 18 and 25 who completed Ramadan. Plasma biochemical and hormonal parameters were analyzed in plasma, a week before Ramadan, in the first and fourth of the fasting month and a week after conclusion. During Ramadan, have been observed a drop of biochemical parameters along daytime, especially those related to glycemia, being these changes stronger in the first week. The concentration of cortisol found to be significantly high during the whole month as a consequence of adaptation to the change of circadian secretion rhythms. Ramadan obliges subject´s organisms to readjust their endocrine and metabolic system in order to preserve the energetic efficiency during daytime. This auto control becomes more efficient as long as the month advances due to physiological adaptations.
Subject(s)
Adolescent , Adult , Humans , Male , Young Adult , Adaptation, Physiological/physiology , Athletic Performance/physiology , Energy Intake/physiology , Fasting/metabolism , Islam , Athletes , Fasting/physiologyABSTRACT
INTRODUCTION: The aim of this pilot study was to evaluate the initial response to 16 weeks of treatment with infliximab and etanercept of disease activity and quality of life in a cohort of 37 patients with established rheumatoid arthritis. PATIENTS AND METHOD: Patients were selected from the Unit of Rheumatology in Hospital Clínico San Cecilio from Granada, refractory to conventional treatment with disease modifying antirheumatic drugs. To assess the disease activity, Disease activity score (DAS28) was used and the measurement of quality of life was evaluated with the Spanish version of the SF-36 Health Survey (SF-36) and the RA-specific questionnaire QoL Scale (Quality of Life in Rheumatoid Arthritis). RESULTS: Preliminary results show a significant decrease in inflammatory activity of the disease and consequently in HRQL scores. The comparison with the general reference population shows a deviation well below average, especially in the "physical function" dimension with a rising response pattern in all dimensions. The correlation between specific scores (QoL-RA scale) and generic ones (SF-36) for HQ-treatment also showed significance, especially with the physical aggregate. DISCUSSION: An important limitation of the present study is the number of patients and the duration of the treatment; despite this, improvements in functional parameters and quality of life are evident and remain roughly stable since the first weeks of treatment. This allow us to continue the study and increase the number of patients. CONCLUSIONS: The preliminary results obtained with TNF-blockers after 16 weeks of treatment in RA objectively show the effectiveness of these drugs and also the perception by the patients of the effect on their quality of life.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Immunoglobulin G/therapeutic use , Quality of Life , Receptors, Tumor Necrosis Factor/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adult , Aged , Drug Administration Schedule , Drug Therapy, Combination , Etanercept , Female , Humans , Infliximab , Male , Middle Aged , Pilot Projects , Severity of Illness Index , Surveys and Questionnaires , Treatment OutcomeABSTRACT
Introducción. El objetivo de este estudio piloto ha sido valorar la respuesta inicial tras 16 semanas de tratamiento con infliximab y etanercept sobre la actividad de la enfermedad y la calidad de vida (CV), en una cohorte de 37 pacientes con artritis reumatoide establecida. Pacientes y método. Los pacientes fueron seleccionados en el Servicio de Reumatología del Hospital Clínico San Cecilio de Granada, por ser refractarios al tratamiento convencional con fármacos antirreumáticos modificadores de la enfermedad. Para evaluar la actividad de la enfermedad se utilizó el índice DAS28 (Disease Activity Score) y para CV, la versión española del Cuestionario de Salud SF-36 (Health Survey SF-36) y el cuestionario específico QoL-RA Scale (Quality of Life in Rheumatoid Arthritis). Resultados. Los resultados preliminares muestran una disminución significativa en la actividad inflamatoria y consecuentemente en las puntuaciones de la CV. La comparación con la población general de referencia muestra una desviación muy por debajo de la media, especialmente en la dimensión función física con un patrón de respuesta ascendente en todas las dimensiones. La correlación entre puntuaciones específicas (QoL-RA Scale) y genéricas (SF-36) de CV postratamiento, también mostraron significación, especialmente con el agregado físico. Discusión. Consideramos una limitación importante del estudio el número de pacientes y el tiempo de evolución postratamiento. No obstante, las mejorías en los diferentes parámetros funcionales y de CV son objetivables y permanecen prácticamente estables desde las primeras semanas de tratamiento, lo que nos permitirá continuar el estudio y ampliar el número de pacientes. Conclusiones. Los resultados preliminares obtenidos con anti-TNF alfa tras 16 semanas de tratamiento en artritis reumatoide, muestran la efectividad de los fármacos objetivamente y subjetivamente según la percepción del paciente sobre su CV (AU)
Introduction. The aim of this pilot study was to evaluate the initial response to 16 weeks of treatment with infliximab and etanercept of disease activity and quality of life in a cohort of 37 patients with established rheumatoid arthritis. Patients and method. Patients were selected from the Unit of Rheumatology in Hospital Clínico San Cecilio from Granada, refractory to conventional treatment with disease modifying antirheumatic drugs. To assess the disease activity, Disease activity score (DAS28) was used and the measurement of quality of life was evaluated with the Spanish version of the SF-36 Health Survey (SF-36) and the RA-specific questionnaire QoL Scale (Quality of Life in Rheumatoid Arthritis). Results. Preliminary results show a significant decrease in inflammatory activity of the disease and consequently in HRQL scores. The comparison with the general reference population shows a deviation well below average, especially in the physical function dimension with a rising response pattern in all dimensions. The correlation between specific scores (QoL-RA scale) and generic ones (SF-36) for HQ-treatment also showed significance, especially with the physical aggregate. Discussion. An important limitation of the present study is the number of patients and the duration of the treatment; despite this, improvements in functional parameters and quality of life are evident and remain roughly stable since the first weeks of treatment. This allow us to continue the study and increase the number of patients. Conclusions. The preliminary results obtained with TNF-blockers after 16 weeks of treatment in RA objectively show the effectiveness of these drugs and also the perception by the patients of the effect on their quality of life (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Quality of Life , Arthritis, Rheumatoid/therapy , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Tumor Necrosis Factors/therapeutic use , Cohort Studies , Surveys and Questionnaires , Informed Consent/standardsABSTRACT
Objetivo. El objetivo del presente estudio ha sido valorar el efecto de infliximab y etanercept, sobre la capacidad funcional y la calidad de vida relacionada con la salud (CVRS) de 13 pacientes, mayores de 65 años, con espondilitis anquilosante (EA). Pacientes y métodos. Se incluyeron de forma consecutiva aquellos pacientes mayores de 65 años, refractarios al tratamiento convencional con fármacos antireumáticos modificadores de la enfermedad (FAME) diagnosticados en el Servicio de Reumatología del Hospital Clínico San Cecilio de Granada. Para evaluar actividad de la enfermedad utilizamos el índice BASDAI (bath ankylosing spondylitis disease activity index); para capacidad funcional y CVRS, el índice BASFI (bath ankylosing spondylitis functional index) y ASQoL (ankylosing spondylitis quality of life) respectivamente. Resultados. Se trata de un estudio piloto para valorar la respuesta a fármacos anti-TNFalfa (bloqueantes del factor de necrosis tumoral alfa) de 13 pacientes con EA mayores de 65 años, en los que se constata la disminución de actividad de la enfermedad. Los valores medios de las puntuaciones del dolor y de la enfermedad (BASDAI), muestran un descenso de 6,72 a 3,67 y de 6,15 a 2,79 respectivamente (p<0,0001), por debajo de 4, considerado como respuesta aceptable. También hubo mejorías significativas en la capacidad funcional (BASFI) pasando de 6,15 a 2,79 (p<0,001) y de la calidad de vida (ASQoL) de 13,85 a 4,22 (p<0,0001). Conclusiones. Nuestros resultados están en la línea de lo informado por otros autores sobre la eficacia de los fármacos anti-TNF, reduciendo significativamente la sintomatología clínica inflamatoria de la enfermedad a las 16 semanas y mejorando la funcionalidad y CV en pacientes con EA, mayores de 65 años(AU)
Background and objectives. The aim of the present study is to assess the impact of infliximab and etanercept, TNF-alpha (tumour necrosis factor-alpha blockers) on functional disability and quality of life in thirteen patients over 65 years-old with ankylosing spondylitis (AS). Patients and methods. We consecutively included patients over 65 years-old, attending our clinic from Rheumatology Service in Hospital Clínico de Granada. These patients were all refractory to conventional therapy with disease-modifying anti-rheumatic drugs (DMARD). Disease activity was assessed using BASDAI index (bath ankylosing spondylitis disease activity index). Functional disability was assessed using BASFI (bath ankylosing spondylitis functional index) and ASQol index (ankylosing spondylitis quality of life index). Results. We present a pilot study with 13 patients over 65 years-old treated with TNF blockers for 16 weeks. A significant decrease in disease activity was observed. Mean values of VAS (visual analogue scale) pain scores and disease decreases significantly after treatment (from 6.72 to 3.67 and 6.15 to 2.79 respectively), less than 4, which is considered an acceptable BASDAI response. Functional ability (BASFI) and health related quality of life (HRQOL) improved significantly from 6.15 to 2.79 and 13.85 to 4.22. Conclusions. Our results are consistent with the data available in the literature about TNF blockers decreasing clinical signs of the disease. Disease activity had significantly decreased 16 weeks after the onset of TNF blocker therapy. Functionality and quality of life have been also improved in elderly people with AS(AU)
Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Quality of Life , Spondylitis, Ankylosing/diagnosis , Spondylitis, Ankylosing/therapy , Antirheumatic Agents/therapeutic use , Pilot Projects , Surveys and Questionnaires , 28599ABSTRACT
BACKGROUND AND OBJECTIVES: The aim of the present study is to assess the impact of infliximab and etanercept, TNF-alpha (tumour necrosis factor-alpha blockers) on functional disability and quality of life in thirteen patients over 65 years-old with ankylosing spondylitis (AS). PATIENTS AND METHODS: We consecutively included patients over 65 years-old, attending our clinic from Rheumatology Service in Hospital Clínico de Granada. These patients were all refractory to conventional therapy with disease-modifying anti-rheumatic drugs (DMARD). Disease activity was assessed using BASDAI index (bath ankylosing spondylitis disease activity index). Functional disability was assessed using BASFI (bath ankylosing spondylitis functional index) and ASQol index (ankylosing spondylitis quality of life index). RESULTS: We present a pilot study with 13 patients over 65 years-old treated with TNF blockers for 16 weeks. A significant decrease in disease activity was observed. Mean values of VAS (visual analogue scale) pain scores and disease decreases significantly after treatment (from 6.72 to 3.67 and 6.15 to 2.79 respectively), less than 4, which is considered an acceptable BASDAI response. Functional ability (BASFI) and health related quality of life (HRQOL) improved significantly from 6.15 to 2.79 and 13.85 to 4.22. CONCLUSIONS: Our results are consistent with the data available in the literature about TNF blockers decreasing clinical signs of the disease. Disease activity had significantly decreased 16 weeks after the onset of TNF blocker therapy. Functionality and quality of life have been also improved in elderly people with AS.
Subject(s)
Activities of Daily Living , Quality of Life , Spondylitis, Ankylosing/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Female , Humans , Male , Pilot Projects , Spondylitis, Ankylosing/physiopathology , Time FactorsABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Aged , Anti-Inflammatory Agents/therapeutic use , Arthritis, Rheumatoid/complications , Sclerosis/drug therapy , Antibodies, Monoclonal/therapeutic use , Sclerosis/etiology , Sclerosis/complicationsABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Craniocerebral Trauma/complications , Arthritis, Rheumatoid/complications , Atlanto-Axial Joint/injuries , Disease Susceptibility , Fractures, BoneABSTRACT
Behçet's disease (BD) is a systemic vasculitic disorder of unknown aetiology characterised by recurrent oral and often genital ulcers, which may be associated with ocular, cutaneous, articular, neurological or vascular involvement. We report a 52-year-old woman diagnosed of neuro-BD who was treated with infliximab with a dramatic response to this treatment.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Behcet Syndrome/drug therapy , Brain Diseases/drug therapy , Behcet Syndrome/complications , Behcet Syndrome/pathology , Brain Diseases/etiology , Brain Diseases/pathology , Female , Humans , Infliximab , Magnetic Resonance Imaging , Middle Aged , Treatment OutcomeSubject(s)
Cardiovascular Diseases/epidemiology , Hypertension/complications , Risk Assessment/methods , Adult , Aged , Cohort Studies , Female , Humans , Male , Middle Aged , SpainABSTRACT
No disponible
Subject(s)
Male , Female , Adult , Aged , Middle Aged , Humans , Cardiovascular Diseases/etiology , Risk Assessment/methods , Hypertension/complications , Cohort Studies , Risk Factors , SpainABSTRACT
AIM: This paper reports a study examining the effects of physical exercise on the quality of life of menopausal women. BACKGROUND: People who perform no type of physical activity have poorer physical and mental health. Despite the well-documented benefits of exercise, ageing women remain largely sedentary, and interventions designed to help them to maintain exercise programmes may prove particularly valuable. Measures should focus on increasing women's confidence so that they can overcome barriers to exercise. Conflicting results have been reported in intervention studies to promote exercise in postmenopausal women. METHODS: Forty-eight menopausal women aged 55-72 years were recruited at a primary care centre as voluntary participants in a quasi-experimental study. They were randomly assigned to one of two groups: control (n = 24) and experimental (n = 24). The experimental group participated in a 12-month programme of cardiorespiratory, stretching, muscle-strengthening and relaxation exercises carried out during two fully supervised exercise sessions per week (total of 3 hours weekly). Health-related quality of life was assessed by using the Quality of Life Profile for Chronically Ill Patients, a generic questionnaire widely used in epidemiological and clinical studies to measure well-being and function, incorporating as an optional module the Kupperman Index of Menopausal Symptomatology. RESULTS: There was a statistically significant improvement in the health-related quality of life of the experimental group, whereas the health-related quality of life of the control group significantly worsened. Menopausal symptoms also significantly improved in the experimental group and significantly worsened in the control group over the 12-month study period. CONCLUSIONS: A customized exercise programme is valuable for improving the health-related quality of life of menopausal women.
